Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
NYXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $20.00
Previous CloseN/A
Volume100.61K
Average Volume (3M)27.00K
Market Cap
$331.53M
Enterprise Value$241.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 13, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding34,386,765
10 Day Avg. Volume18,157
30 Day Avg. Volume27,001
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)98.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.27Price Target Upside63.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Nyxoah News
PremiumCompany Announcements
Nyxoah Prepares for U.S. Launch Following Strong 2024 Performance
PremiumCompany Announcements
Nyxoah to Announce Q4 and FY 2024 Financial Results
PremiumCompany Announcements
Nyxoah to Present at Oppenheimer Healthcare Conference
PremiumCompany Announcements
Nyxoah Launches Genio Therapy in Middle East with First UAE Implantation
PremiumCompany Announcements
Nyxoah Receives Transparency Notification from BlackRock
PremiumCompany Announcements
Nyxoah Receives Transparency Notification from BlackRock, Inc.---
Bulls Say, Bears Say
Bulls Say
Financial HealthNyxoah reported a proforma cash position of €95.6M, indicating strong financial health.
Market ExpansionThe commercial launch of Genio in England with its first implants successfully performed highlights Nyxoah's expansion in the European market.
Bears Say
Market ChallengesThe European market will continue to be difficult to grow and penetrate, posing a challenge for Nyxoah's expansion efforts in that region.
---
Ownership Overview
11.80%
Insiders
5.54% Mutual Funds
9.10% Other Institutional Investors
73.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $6.76 and its highest was $20.00 in the past 12 months.
What is Nyxoah’s market cap?
Nyxoah’s market cap is $331.53M.
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is Mar 13, 2025 which is today.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on Nov 06, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.494 by -$0.046.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -0.51.
How many shares outstanding does Nyxoah have?
Nyxoah has 34,386,765 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.494. Following the earnings report the stock price went down -3.6%.
Which hedge fund is a major shareholder of Nyxoah?
Currently, no hedge funds are holding shares in NYXH
---
Nyxoah Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.27 (63.52% Upside)
$16.27 (63.52% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 253.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.3%
Last 30 Days ▼ 11.5%
Last 30 Days ▼ 11.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.47%
12-Months-Change
Fundamentals
Return on Equity
-49.39%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
---
NYXH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a positive outlook with strong clinical trial results, significant regulatory progress, and successful capital raising efforts. However, there are challenges related to increased operational losses, FDA inspection delays, and uncertainties in reimbursement strategies.Read More>---
NYXH Stock 12 Month Forecast
Average Price Target
$16.27
▲(63.52% Upside)
Technical Analysis
Irhythm Technologies
―
Inspire Medical Systems
―
Senseonics Holdings
―
Stereotaxis
―
NovoCure
―
Smith & Nephew Snats
―
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+22.77%
reiterated a buy rating 3 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +22.77% per trade.
---